Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01592240 · ClinicalTrials.gov registry record · Phase 2
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 354
- Enrollment target
NCT01592240: Completed Phase 2 study, sponsored by Pfizer.
NCT01592240 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 354 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (166% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01592240, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 354 participants
- Enrollment target
Study Summary
To evaluate the Low Density Lipoprotein-Cholesterol (LDL-C) lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in subjects with high cholesterol whose LDL-cholesterol is \>/=80 mg/dL on background treatment with a statin.
Interventions
- DRUG PBO
- DRUG 200mg PF-04950615 (RN316)
- DRUG 300mg PF-04950615 (RN316)
- DRUG PF-04950615
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
What the finished NCT01592240 record still lists
NCT01592240 is an interventional study that assigns participants to a tested intervention. The registered 354 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (166% higher).
The record links to 0 conditions, and to 4 interventions - of which PBO is the first listed.
NCT01592240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01592240 about?
NCT01592240 is a clinical study titled "Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin". To evaluate the Low Density Lipoprotein-Cholesterol (LDL-C) lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in subjects with high cholesterol whose LDL-cholesterol is \>/=80 mg/dL on background treatment with a statin.
What is the current status of trial NCT01592240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 354 participants. The study started on 2012-07. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01592240?
The interventions under investigation include: PBO (DRUG), 200mg PF-04950615 (RN316) (DRUG), 300mg PF-04950615 (RN316) (DRUG), PF-04950615 (DRUG).
Who is sponsoring clinical trial NCT01592240?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01592240's enrollment target sits among peer trials
354 128th of 2000 higher than 1,872 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
- NCT05729256 · 354 participants · NA
Alcohol and "Heat of the Moment" Sexual Decision Making
- NCT06507618 · 354 participants · Phase 3
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia